

Pre - PA Allowance

None

Prior-Approval Requirements

Age 13 years of age or older

Diagnosis

Patient must have the following:

1. Giant cell tumor of bone
 - a. Tumor is unresectable or surgical resection is not recommended
 - b. Pre-existing hypocalcemia must be corrected prior to initiating therapy
 - c. **NO** concurrent use with another RANKL- inhibitor (see Appendix 1)
-

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Bone metastases from solid tumors
2. Multiple myeloma

AND ALL of the following for **BOTH** indications above:

- a. At high risk for skeletal-related events
- b. Pre-existing hypocalcemia must be corrected prior to initiating therapy
- c. Inadequate treatment response, intolerance, or contraindication to **ONE** of the following:
 - i. IV Bisphosphonate
 - ii. Pamidronate
 - iii. Zoledronic acid

3. Hypercalcemia of malignancy

- a. Disease must have relapsed or progressed after bisphosphonate therapy

AND the following for **ALL** indications:

- a. **NO** concurrent use with another RANKL-inhibitor (see Appendix 1)

Prior - Approval Limits

Quantity 5 vials per 84 days

Duration 3 months

Prior – Approval *Renewal* Requirements

Age 13 years of age or older

Diagnosis

Patient must have the following:

1. Giant cell tumor of bone
 - a. **NO** concurrent use with another RANKL-inhibitor (see Appendix 1)
-

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Bone metastases from solid tumors
2. Multiple myeloma
3. Hypercalcemia of malignancy

AND the following for **ALL** indications:

- a. **NO** concurrent use with another RANKL-inhibitor (see Appendix 1)

Prior - Approval *Renewal* Limits

Quantity 3 vials per 84 days

Duration 12 months

Appendix 1 - List of RANKL Inhibitors



Federal Employee Program.

XGEVA
(denosumab)

Generic Name	Brand Name
denosumab	Prolia
denosumab	Xgeva